Occult mediastinal lymph node metastasis in NSCLC patients diagnosed as clinical N0-1 by preoperative integrated FDG-PET/CT and CT: Risk factors, pattern, and histopathological study

Lung Cancer

Volumn 71, Issue 3, 2011, Pages 333-337

  Kanzaki, Ryu ^a   Higashiyama, Masahiko ^a   Fujiwara, Ayako ^a   Tokunaga, Toshiteru ^a   Maeda, Jun ^a   Okami, Jiro ^a   Kozuka, Takenori ^a   Hosoki, Takuya ^b   Hasegawa, Yoshihisa ^b   Takami, Motohisa ^b   Tomita, Yasuhiko ^a   Kodama, Ken ^a  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b Morinomiya Clinic PET Center   (Japan)

Author keywords

Computed tomography; Diagnosis; Lung cancer; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; FEMALE; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM LYMPH NODE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RISK FACTOR; TUMOR LOCALIZATION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INCIDENCE; LYMPHATIC METASTASIS; MALE; MEDIASTINUM; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79851516526     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.06.008     Document Type: Article

References (19)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43-66.
2. Roth J.A., Atkinson E.N., Fossella F., Komaki R., Bernadette R.M., Putnam J.B., et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 1998, 21:1-6.
3. Rusch V.W., Albain K.S., Crowley J.J., Rice T.W., Lonchyna V., McKenna R., et al. Surgical resection of stage IIIA and stage IIIB non-small-cell lung cancer after concurrent induction chemoradiotherapy. A Southwest Oncology Group trial. J Thorac Cardiovasc Surg 1993, 105:97-104. discussion 104-6.
4. Rosell R., Gomez-Codina J., Camps C., Maestre J., Padille J., Canto A., et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994, 330:153-158.
5. Cerfolio R.J., Ojha B., Bryant A.S., Raghuveer V., Mountz J.M., Bartolucci AA The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer. Ann Thorac Surg 2004, 78:1017-1023. discussion 1017-23.
6. Al-Sarraf N., Aziz R., Gately K., Lucey J., Wilson L., McGovern E., et al. Pattern and predictors of occult mediastinal lymph node involvement in non-small cell lung cancer patients with negative mediastinal uptake on positron emission tomography. Eur J Cardiothorac Surg 2008, 33:104-109.
7. Lee P.C., Port J.L., Korst R.J., Liss Y., Meherally D.N., Altorki N.K. Risk factors for occult mediastinal metastases in clinical stage I non-small cell lung cancer. Ann Thorac Surg 2007, 84:177-181.
8. Cerfolio R.J., Bryant A.S., Ohja B., Bartolucci A.A. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg 2005, 130:151-159.
9. Mountain C.F. Revisions in the International System for Staging Lung Cancer. Chest 1997, 111:1710-1717.
10. Naruke T., Suemasu K., Ishikawa S. Lymph node mapping and curability at various levels of metastasis in resected lung cancer. J Thorac Cardiovasc Surg 1978, 76:832-839.
11. World Health Organization Histological Typing of Lung and Pleural Tumours 2004, IARCPress, Lyon. 4th ed.
12. Cerfolio R.J., Bryant A.S., Eloubeidi M.A. Routine mediastinoscopy and esophageal ultrasound fine-needle aspiration in patients with non-small cell lung cancer who are clinically N2 negative: a prospective study. Chest 2006, 130:1791-1795.
13. Mori K., Yokoi K., Saito Y., Tominaga K., Miyazawa N. Diagnosis of mediastinal lymph node metastases in lung cancer. Jpn J Clin Oncol 1992, 22:35-40.
14. Kamiyoshihara M., Kawashima O., Ishikawa S., Morishita Y. Mediastinal lymph node evaluation by computed tomographic scan in lung cancer. J Cardiovasc Surg 2001, 42:119-124.
15. Shields T.W. Pathology of carcinoma of the lung. General Thoracic Surgery 2009, vol. II:1311-1340. Lippincott Williams & Wilkins, New York. 7th ed.
16. Downey R.J., Akhurst T., Gonen M., Vincent A., Bains M.S., Larson S., et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 2004, 22:3255-3260.
17. Takamochi K., Yoshida J., Murakami K., Niho S., Ishii G., Nishimura M., et al. Pitfalls in lymph node staging with positron emission tomography in non-small cell lung cancer patients. Lung Cancer 2005, 47:235-242.
18. Nomori H., Watanabe K., Ohtsuka T., Naruke T., Suemasu K., Uno K. The size of metastatic foci and lymph nodes yielding false-negative and false-positive lymph node staging with positron emission tomography in patients with lung cancer. J Thorac Cardiovasc Surg 2004, 127:1087-1092.
19. Naruke T., Tsuchiya R., Kondo H., Nakayama H., Asamura H. Lymph node sampling in lung cancer: how should it be done?. Eur J Cardiothorac Surg 1999, 16(Suppl. 1):S17-S24.